Revvity (RVTY) Expected to Announce Quarterly Earnings on Monday

Revvity (NYSE:RVTY) is projected to issue its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $1.55 per share and revenue of $759.8050 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Revvity Trading Down 0.0%

Shares of RVTY opened at $108.48 on Friday. The firm’s 50-day moving average is $103.96 and its two-hundred day moving average is $95.44. Revvity has a twelve month low of $81.36 and a twelve month high of $128.04. The company has a current ratio of 1.75, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $12.30 billion, a P/E ratio of 54.51, a PEG ratio of 3.31 and a beta of 1.05.

Revvity announced that its board has approved a share repurchase plan on Monday, October 27th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 8.7% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s dividend payout ratio is 14.07%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity during the 2nd quarter valued at $32,000. MUFG Securities EMEA plc purchased a new position in Revvity during the 2nd quarter valued at about $34,000. Headlands Technologies LLC purchased a new position in Revvity during the second quarter valued at approximately $49,000. EverSource Wealth Advisors LLC boosted its stake in shares of Revvity by 25.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 900 shares of the company’s stock valued at $87,000 after buying an additional 185 shares during the period. Finally, Nomura Holdings Inc. acquired a new stake in Revvity during the third quarter valued at $270,000. 86.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wells Fargo & Company upped their target price on Revvity from $102.00 to $107.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Evercore ISI reiterated an “outperform” rating on shares of Revvity in a research note on Monday, January 5th. The Goldman Sachs Group started coverage on Revvity in a research note on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 target price for the company. Barclays raised their price target on shares of Revvity from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Guggenheim assumed coverage on Revvity in a research note on Wednesday, October 15th. They set a “neutral” rating for the company. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $113.91.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.